The CHASIT Study Explores New Treatment Approach for Advanced Urothelial Cancer
The CHASIT study assumes that utilizing sequential chemo-immunotherapy may yield a pCR rate of ≥30% in treating patients with locally advanced, unresectable, or clinically node-positive urothelial cancer (UC) at stage cT4NxM0 or cTxN1-N3M0, surpassing the historical 15% pCR rate with induction chemotherapy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
